Marker Therapeutics Inc
MRKR
Company Profile
Business description
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
Contact
2450 Holcombe Boulevard
Suite e BCM-A, MS: BCM251
HoustonTX77021
USAT: +1 713 400-6400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
5
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,287.90 | 84.00 | 1.02% |
| CAC 40 | 7,573.76 | 37.50 | 0.50% |
| DAX 40 | 22,271.67 | 29.22 | 0.13% |
| Dow JONES (US) | 40,227.59 | 114.09 | 0.28% |
| FTSE 100 | 8,417.34 | 2.09 | 0.02% |
| HKSE | 21,970.19 | 1.77 | -0.01% |
| NASDAQ | 17,366.13 | 16.81 | -0.10% |
| Nikkei 225 | 35,839.99 | 134.25 | 0.38% |
| NZX 50 Index | 12,025.45 | 73.44 | -0.61% |
| S&P 500 | 5,528.75 | 3.54 | 0.06% |
| S&P/ASX 200 | 8,070.60 | 73.50 | 0.92% |
| SSE Composite Index | 3,287.45 | 0.96 | -0.03% |